A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures

PARP inhibitors are approved for the treatment of solid tumor types that frequently harbor alterations in the key homologous recombination (HR) genes, BRCA1/2. Other tumor types, such as lung cancer, may also be HR deficient, but the frequency of such cases is less well characterized. Specific DNA a...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:NPJ Precis Oncol
Autori principali: Diossy, Miklos, Sztupinszki, Zsofia, Borcsok, Judit, Krzystanek, Marcin, Tisza, Viktoria, Spisak, Sandor, Rusz, Orsolya, Timar, Jozsef, Csabai, István, Fillinger, Janos, Moldvay, Judit, Pedersen, Anders Gorm, Szuts, David, Szallasi, Zoltan
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group UK 2021
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8213828/
https://ncbi.nlm.nih.gov/pubmed/34145376
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41698-021-00199-8
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi